Gentian Diagnostics AS

Total Valuation

Gentian Diagnostics AS carries a market capitalization of 618.34M, placing it among publicly traded companies globally. Its enterprise value stands at 909.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Gentian Diagnostics AS currently has 15.42M shares outstanding.

Valuation Ratios

Gentian Diagnostics AS trades at a trailing price-to-earnings ratio of 23.39. The price-to-sales ratio is 6.04, and the price-to-book ratio stands at -8.23.

Enterprise Valuation

On an enterprise value basis, Gentian Diagnostics AS trades at an EV/EBITDA multiple of 46.01 and an EV/FCF ratio of 23.23. The EV/Sales ratio of 5.57 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 46.01 provides insight into valuation relative to core operating earnings.

Financial Position

Gentian Diagnostics AS maintains a current ratio of 5.47, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.60, indicating elevated leverage, while an interest coverage ratio of 4.51 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Gentian Diagnostics AS has paid -21.29M in income taxes, reflecting an effective tax rate of 23.14.

Stock Price Statistics

Gentian Diagnostics AS's stock has declined approximately -37.6947% over the past 52 weeks. The 50-day moving average sits at 38.17, while the 200-day moving average is 47.68.

Income Statement

Over the trailing twelve months, Gentian Diagnostics AS generated 163.38M in revenue and converted that into 42.19M in net income, yielding earnings per share of 2.67. EBITDA reached 19.78M, while operating income came in at 19.78M.

Balance Sheet

Gentian Diagnostics AS holds 80.25M in cash and equivalents against 3.15M in total debt, resulting in a net debt position of -80.25M. Total book value stands at -119.88M, with working capital of 136.80M providing operational flexibility.

Cash Flow

Gentian Diagnostics AS produced 19.89M in operating cash flow over the past twelve months. After subtracting -10.43M in capital expenditures, free cash flow totaled 9.47M - equivalent to 0.61 per share.

Margins

Gentian Diagnostics AS operates with a gross margin of 54.19, reflecting its pricing power and cost economics. The operating margin of 12.10 and net profit margin of 25.83 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 14.62 indicates the proportion of earnings distributed to shareholders.

Scores

Gentian Diagnostics AS posts an Altman Z-Score of 18.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.